Silence Therapeutics plc (SLN)
SLN Stock Price Chart
Explore Silence Therapeutics plc interactive price chart. Choose custom timeframes to analyze SLN price movements and trends.
SLN Company Profile
Discover essential business fundamentals and corporate details for Silence Therapeutics plc (SLN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Sept 2020
Employees
116.00
CEO
Iain Gladstone Ross
Description
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
SLN Financial Timeline
Browse a chronological timeline of Silence Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.14, while revenue estimate is $1.17m.
Earnings released on 7 May 2026
EPS came in at -$0.32 surpassing the estimated -$0.33 by +3.03%, while revenue for the quarter reached $422.00k , missing expectations by -66.37%.
Earnings released on 5 Mar 2026
EPS came in at -$0.25 surpassing the estimated -$0.32 by +21.88%, while revenue for the quarter reached $39.00k , missing expectations by -98.66%.
Earnings released on 6 Nov 2025
EPS came in at -$0.45 falling short of the estimated -$0.40 by -12.50%, while revenue for the quarter reached $159.00k , missing expectations by -94.88%.
Earnings released on 7 Aug 2025
EPS came in at -$0.54 falling short of the estimated -$0.27 by -100.00%, while revenue for the quarter reached $224.00k , missing expectations by -93.11%.
Earnings released on 8 May 2025
EPS came in at -$0.60 falling short of the estimated -$0.18 by -233.33%, while revenue for the quarter reached $142.00k , missing expectations by -93.88%.
Earnings released on 27 Feb 2025
EPS came in at $0.27 surpassing the estimated -$0.45 by +160.00%, while revenue for the quarter reached $24.33m , beating expectations by +259.38%.
Earnings released on 14 Nov 2024
EPS came in at -$0.75 falling short of the estimated -$0.42 by -78.57%, while revenue for the quarter reached $1.14m , missing expectations by -79.94%.
Earnings released on 16 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.23 by +78.26%, while revenue for the quarter reached $15.70m , beating expectations by +148.46%.
Earnings released on 14 Nov 2023
EPS came in at -$0.28 surpassing the estimated -$0.56 by +50.00%, while revenue for the quarter reached $2.80m , missing expectations by -4.02%.
Earnings released on 16 Aug 2023
EPS came in at -$0.36 surpassing the estimated -$0.59 by +38.98%, while revenue for the quarter reached $9.10m , beating expectations by +138.91%.
Earnings released on 16 May 2023
EPS came in at -$0.35 surpassing the estimated -$0.51 by +31.37%, while revenue for the quarter reached $11.37m , beating expectations by +261.97%.
Earnings released on 10 Nov 2022
EPS came in at -$0.25 surpassing the estimated -$0.60 by +58.33%, while revenue for the quarter reached $3.37m .
Earnings released on 11 Aug 2022
EPS came in at -$1.20 falling short of the estimated -$0.60 by -99.45%, while revenue for the quarter reached $3.64m .
Earnings released on 16 May 2022
EPS came in at -$0.77 falling short of the estimated -$0.62 by -24.23%, while revenue for the quarter reached $5.72m .
Earnings released on 17 Mar 2022
EPS came in at -$0.42 surpassing the estimated -$0.62 by +32.26%, while revenue for the quarter reached $3.41m , missing expectations by -62.43%.
SLN Stock Performance
Access detailed SLN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
